Bronchial Rheoplasty for Chronic Bronchitis: Results from a Canadian Feasibility Study with RheOx®
International Journal of Chronic Obstructive Pulmonary Disease · 2024
DOI: 10.2147/copd.s464506 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2024. Verfasst von Marc Fortin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine and Thoracic Surgery, University of Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ),…. Hauptthemen laut MEDLINE: Feasibility Studies, Bronchitis, Chronic, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: GALA Therapeutics.
Abstract (Originalsprache)
Purpose
Chronic bronchitis (CB), a chronic obstructive pulmonary disease (COPD) phenotype defined by persistent mucus hypersecretion and cough, is associated with poor quality of life, exacerbations, and lung function impairment. Bronchial Rheoplasty (BR) delivers non-thermal pulsed electric fields to airway epithelium and submucosa. Preliminary studies demonstrated reduced airway goblet cell hyperplasia and symptom improvement in response to BR. This study aimed to further assess the safety and clinical feasibility of BR in the setting of CB. Patients and Methods: This 3-center, single-arm study evaluated the safety and feasibility of BR in Canadian patients. The major inclusion criteria were the sum of CAT first 2 questions (cough and mucus) ≥ 7 out of 10 and FEV1 ≥ 30% predicted. Right-sided airways were treated first; left, 1 month later. Serious adverse events (SAEs) were tabulated through 12 months. Outcomes were evaluated using the SGRQ and CAT.
Results
Ten patients with CB were enrolled and followed for 12 months. The BR procedure was successful in all patients (mean age 69 ± 5.8 years, post-BD FEV1 77.1 ± 28.3, SGRQ 56.2 ± 8.8, CAT 25.4 ± 4.7). Only one SAE, a COPD exacerbation 13 days following the BR procedure, was considered device related. No additional SAEs occurred through 12 months, and 90% of the patients were CAT responders (≥ 2-point improvement) at 3 and 6 months. Similar results were observed in SGRQ.
Conclusion
BR was safe and well-tolerated. Meaningful symptom improvement was observed through 12 months, suggesting BR may be a viable treatment option for patients with CB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary Medicine and Thoracic Surgery, University of Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Quebec City, Quebec, Canada.
- Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
- Division of Thoracic Surgery, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.
Förderung
- GALA Therapeutics
Zitieren
APA
Fortin, M., Dorscheid, D. R., Liberman, M., Martel, S., & Shaipanich, T. (2024). Bronchial Rheoplasty for Chronic Bronchitis: Results from a Canadian Feasibility Study with RheOx®. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s464506
Vancouver
Fortin M, Dorscheid DR, Liberman M, Martel S, Shaipanich T. Bronchial Rheoplasty for Chronic Bronchitis: Results from a Canadian Feasibility Study with RheOx®. International Journal of Chronic Obstructive Pulmonary Disease. 2024. doi:10.2147/copd.s464506
BibTeX
@article{Fortin2024,
author = {Fortin, Marc and Dorscheid, Del R and Liberman, Moishe and Martel, Simon and Shaipanich, Tawimas},
title = {Bronchial Rheoplasty for Chronic Bronchitis: Results from a Canadian Feasibility Study with RheOx®},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2024},
doi = {10.2147/copd.s464506}
}
EUVIMED